Type B Insulin Resistance Developing During Interferon-α Therapy
نویسندگان
چکیده
منابع مشابه
Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
BACKGROUND/AIMS Chronic hepatitis C virus (HCV) infection is associated with a higher risk of the development of insulin resistance. If HCV is a causal factor for insulin resistance, then clearance of HCV might decrease insulin resistance. The aim of this study was to elucidate the effects of clearance of HCV on insulin resistance. METHODS We analyzed 28 patients with HCV infection who receiv...
متن کاملChronic hepatitis B with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy.
Interferon alpha is a molecule frequently used in the treatment of chronic hepatitis B, C, and D, with immunomodulatory and antiviral activity. It is also used in some cancer types. It has been widely claimed that interferon alpha triggers autoimmunity, with its broad adverse effect profile. Here we present the case of a 29-year-old male patient with chronic hepatitis B diagnosis who developed ...
متن کاملImmunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report
Type B insulin resistance is a rare syndrome characterized by fluctuating glucose levels (ranging from hyperglycemia with extreme insulin resistance to intractable hypoglycemia without exogenous insulin administration), high serum insulin levels, and insulin receptor autoantibodies. Most cases occur in the African American population in association with other underlying autoimmune systemic dise...
متن کاملdystrophic-anagen effluvium occurring during pegylated interferon-α-2a/ribavirin therapy
introduction various types of dermatological manifestations have been reported due to hepatitis c virus (hcv) infection and antihcv therapy. some of them have been described during ifn-based therapies. peg-ifn-α-2a/rbv combination is used as the international standard of treatment for hcv infection for a long time. the combination therapy yields an adverse-event profile similar to standard int...
متن کاملCombining targeted therapy with immunotherapy (interferon-α)
Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAF(V600)-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is < 9 mo. Combining imatinib with immunotherapy (peginterferon α-2b) in GIST showed significant induction of antitumor immunity and highly ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endocrine Practice
سال: 2009
ISSN: 1530-891X
DOI: 10.4158/ep.15.2.153